Page last updated: 2024-12-04

glyoxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glyoxylic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glyoxylic acid : A 2-oxo monocarboxylic acid that is acetic acid bearing an oxo group at the alpha carbon atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID760
CHEMBL ID1162545
CHEBI ID16891
MeSH IDM0098078

Synonyms (84)

Synonym
alpha-ketoacetic acid
CHEBI:16891 ,
glyoxylsaeure
glyoxalsaeure
oxoethanoic acid
wln: vhvq
nsc-27785
oxoacetic acid
NSC27785 ,
oxalaldehydic acid
formylformic acid
.alpha.-ketoacetic acid
glyoxalic acid
formic acid, formyl-
acetic acid, oxo-
kyselina glyoxylova [czech]
nsc 27785
einecs 206-058-5
brn 0741891
563-96-2
formic acid, formyl
glyoxylic acid (8ci)
glv ,
ccris 1455
hsdb 5559
acetic acid, oxo- (9ci)
acetic acid, oxo
298-12-4
C00048
glyoxylic acid
2-oxoacetic acid
bdbm19472
oxaldehydic acid
DB04343
0ADD8E81-5E77-4171-9241-E74AC05D4C8D
CHEMBL1162545
2-oxoacetate
AKOS005367012
G0366
STL168883
jq39c92hh6 ,
4-03-00-01489 (beilstein handbook reference)
unii-jq39c92hh6
kyselina glyoxylova
acetic acid, 2-oxo-
ec 206-058-5
FT-0626797
glyoxylic acid [who-dd]
glyoxylic acid [mi]
glyoxylic acid [inci]
allantoin impurity a [ep impurity]
glyoxylic acid [hsdb]
glyoxylic acid, 50% w/w aq. soln
glyoxilic acid
ohcco2h
(oxo)acetic acid
W-105518
ochcooh
mfcd00006958
DTXSID5021594
F2191-0150
c2h2o3
alpha-ketoaceticacid
glyoxylic acid (50% in water)
dioxymethylene formaldehyde
formylformate
alpha-ketoacetate
a-ketoacetic acid
a-ketoacetate
oxalaldehydate
oxoethanoate
HY-79494
CS-W019807
glyoxalic acid pound 50% in water pound(c)
glyoxalate; glyoxylate
Q413552
EN300-20485
STR06186
glyoxylic acid 50%
AMY40947
nsc 27785;formylformic acid;oxalaldehydic acid
D70821
2-oxoacetic acid (50% in water)
2-oxoaceticacid

Research Excerpts

Overview

Glyoxylic acid is a tartaric acid degradation product formed in model wine solutions containing iron. Its production is greatly increased by exposure to UV-visible light.

ExcerptReferenceRelevance
"Glyoxylic acid is a tartaric acid degradation product formed in model wine solutions containing iron and its production is greatly increased by exposure to UV-visible light. "( Photoproduction of glyoxylic acid in model wine: Impact of sulfur dioxide, caffeic acid, pH and temperature.
Barril, C; Clark, AC; Grant-Preece, P; Schmidtke, LM, 2017
)
2.23

Toxicity

ExcerptReferenceRelevance
" In whole animals, inhibition of pyruvate carboxylase may contribute to benzoate toxicity and the adverse influence of glyoxylate on benzoate therapy."( Potentiation of benzoate toxicity by glyoxylate. Inhibition of pyruvate carboxylase and the urea cycle.
Cyr, DM; Tremblay, GC, 1989
)
0.28
" These results indicate that COM, and not glyoxylate or glycolaldehyde, is the toxic metabolite responsible for the acute tubular necrosis and renal failure that is observed in EG-poisoned patients."( Calcium oxalate, and not other metabolites, is responsible for the renal toxicity of ethylene glycol.
Cenac, TA; Guo, C; Li, Y; McMartin, KE, 2007
)
0.34
" Using genetically modified mice, we herein report GO as a safe and efficient target for substrate reduction therapy (SRT) in PH1."( Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
Luis-Lima, S; Martin-Higueras, C; Salido, E, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis indicated that pretreatment significantly decreased total body clearance (267."( Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water.
Bull, RJ; Gonzalez-Leon, A; Schultz, IR; Xu, G, 1997
)
0.3
" The development and evaluation of the PBPK model was based upon previously published pharmacokinetic studies coupled with measured blood and tissue partition coefficients and rates of in vitro metabolism of glyoxylic acid to oxalic acid, glycine and other metabolites using primary hepatocytes isolated from male Wistar rats and humans."( Extension of a PBPK model for ethylene glycol and glycolic acid to include the competitive formation and clearance of metabolites associated with kidney toxicity in rats and humans.
Bartels, MJ; Corley, RA; Creim, J; Hansen, SC; McMartin, KE; Saghir, SA; Snellings, WM, 2011
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Intracellular fluorescent labeling combined with histofluorescence indicates that the previously identified L29 facilitator neurons are not serotonergic."( Localization of potential serotonergic facilitator neurons in Aplysia by glyoxylic acid histofluorescence combined with retrograde fluorescent labeling.
Hawkins, RD, 1989
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Chronic daily dosing caused lowering of these metabolites and a delay in the return of lactate to basal levels for 48 hr after the final dose."( Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate.
Evans, OB; Stacpoole, PW, 1982
)
0.26
"Krapp-Hydroxyanthrachinone given orally will, in a dosage of 150-200 mg, inhibit the intra-renal crystallization of calcium oxalate in the rabbit kidney following Glyoxalate intoxication."( [Experimental and clinical studies concerning the influence of natural substances on the crystallization of calcium oxalate (author's transl)].
Berg, W; Bothor, C; Schneider, HJ, 1982
)
0.26
" Biochemical dosage of proteins and of norepinephrine was also performed, and morphological data were compared with biochemical ones."( Age-related changes in catecholaminergic nerve fibers of rat heart and coronary vessels.
Bruzzone, P; Cavallotti, C; Mancone, M; Tranquilli Leali, F,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
aldehydic acidA monocarboxylic acid derived from any dicarboxylic acid that has a retained name by the formal reduction of one of the carboxy groups to a formyl group. The resulting structure, also known as a semialdehyde, may be named by replacing the ending '...ic acid' of the retained name of the dicarboxylic acid by the ending '...aldehydic acid'. Aldehydic acids therefore contain one carboxy group and one aldehyde group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (36)

PathwayProteinsCompounds
Metabolism14961108
The citric acid (TCA) cycle and respiratory electron transport14756
Pyruvate metabolism and Citric Acid (TCA) cycle4146
Pyruvate metabolism2026
Regulation of pyruvate dehydrogenase (PDH) complex914
Amino acid and derivative metabolism250260
Glyoxylate metabolism and glycine degradation2037
Alanine Metabolism513
Glycine and Serine Metabolism2452
Primary Hyperoxaluria Type I513
Pyruvate Carboxylase Deficiency513
Lactic Acidemia513
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Non-Ketotic Hyperglycinemia2452
Hyperglycinemia, Non-Ketotic2452
3-Phosphoglycerate Dehydrogenase Deficiency2452
Glycolate and Glyoxylate Degradation1522
Secondary Metabolites: Glyoxylate Cycle715
Glycolate and Glyoxylate Degradation II1221
Glycine Metabolism1127
Glyoxylate Cycle613
Urate Degradation to Glyoxylate714
Butanoate Metabolism922
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
L-Alanine + Glyoxylic acid = Pyruvic acid + Glycine ( Glycolysis and Gluconeogenesis )24
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
superpathway of glyoxylate cycle024
glycine biosynthesis from alanine02
allantoin degradation07
superpathway of glycine biosynthesis04
Principal pathways of carbon metabolism07
Glycine metabolism06
Metabolism overview078
Biochemical pathways: part I0466
Allantoin degradation616
PCO cycle824

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
diaminopimelate biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lysine biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lysine biosynthetic process via diaminopimelate4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
diaminopimelate biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
small molecule metabolic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
4-hydroxy-tetrahydrodipicolinate synthase activity4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lyase activity4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
identical protein binding4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasm4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
cytosol4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
cytosol4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID388791Inhibition of Escherichia coli DHDPS2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Irreversible inhibition of dihydrodipicolinate synthase by 4-oxo-heptenedioic acid analogues.
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (847)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990187 (22.08)18.7374
1990's133 (15.70)18.2507
2000's222 (26.21)29.6817
2010's248 (29.28)24.3611
2020's57 (6.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.60 (24.57)
Research Supply Index6.79 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index133.91 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (53.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews51 (5.74%)6.00%
Case Studies6 (0.67%)4.05%
Observational1 (0.11%)0.25%
Other831 (93.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]